Breaking News

Curia Opens Expanded New Mexico Manufacturing Campus

$200M investment boosts sterile injectable drug production capacity in Albuquerque.

Editor’s Take: This expansion strengthens Curia’s global network of sterile fill-finish facilities. Earlier this year, Curia completed a $4 million upgrade of its two aseptic suites in Valladolid, Spain, and announced expansion plans at its Glasgow, UK facility.

Curia Global Inc., a global research, development and manufacturing organization, has opened its expanded campus in Albuquerque, New Mexico.

The expanded Albuquerque campus specializes in aseptic fill-finish and lyophilization services, which are complemented by automated visual inspection and packaging technologies. The $200 million investment added 70,000 square feet to the facility’s 200,000 square foot manufacturing footprint, creating space to house two new isolated filling lines—a VarioSys flexible filling line that supports syringes, cartridges and vials as well as a high-speed vial line that can handle 1,000 L batch sizes while filling at a speed up to 400 vials per minute. These capabilities are further supported by the facility’s Sterile University, a sterile manufacturing training program.

“Customers increasingly need reliable domestic manufacturing capacity for critical injectable vaccines and medicines,” said Philip Macnabb, CEO of Curia. “With this expansion, we can provide increased capacity and advanced technology at an established facility that has a 40-year history as a center of excellence for sterile drug product manufacturing.”

The expansion was supported through cooperative agreement IDSEP230064 with the Biomedical Advanced Research and Development Authority (BARDA), part of ASPR within HHS, in coordination with the Department of War’s Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense. The collaboration is intended to strengthen domestic production capacity for injectable medicines. The State of New Mexico also supported the project through assistance from the Local Economic Development Act (LEDA) job creation fund.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters